[HTML][HTML] In Silico Oncology: Quantification of the In Vivo Antitumor Efficacy of Cisplatin-Based Doublet Therapy in Non-Small Cell Lung Cancer (NSCLC) through a …
E Kolokotroni, D Dionysiou, C Veith… - PLoS Computational …, 2016 - journals.plos.org
The 5-year survival of non-small cell lung cancer patients can be as low as 1% in advanced
stages. For patients with resectable disease, the successful choice of preoperative …
stages. For patients with resectable disease, the successful choice of preoperative …
In Silico Oncology: Quantification of the In Vivo Antitumor Efficacy of Cisplatin-Based Doublet Therapy in Non-Small Cell Lung Cancer (NSCLC) through a Multiscale …
E Kolokotroni, D Dionysiou, C Veith, YJ Kim… - Plos Computational …, 2016 - europepmc.org
The 5-year survival of non-small cell lung cancer patients can be as low as 1% in advanced
stages. For patients with resectable disease, the successful choice of preoperative …
stages. For patients with resectable disease, the successful choice of preoperative …
[HTML][HTML] In Silico Oncology: Quantification of the In Vivo Antitumor Efficacy of Cisplatin-Based Doublet Therapy in Non-Small Cell Lung Cancer (NSCLC) through a …
E Kolokotroni, D Dionysiou, C Veith… - PLoS Computational …, 2016 - ncbi.nlm.nih.gov
The 5-year survival of non-small cell lung cancer patients can be as low as 1% in advanced
stages. For patients with resectable disease, the successful choice of preoperative …
stages. For patients with resectable disease, the successful choice of preoperative …
In Silico Oncology: Quantification of the In Vivo Antitumor Efficacy of Cisplatin-Based Doublet Therapy in Non-Small Cell Lung Cancer (NSCLC) through a Multiscale …
E Kolokotroni, D Dionysiou, C Veith… - PLoS …, 2016 - search.ebscohost.com
The 5-year survival of non-small cell lung cancer patients can be as low as 1% in advanced
stages. For patients with resectable disease, the successful choice of preoperative …
stages. For patients with resectable disease, the successful choice of preoperative …
[引用][C] In Silico Oncology: Quantification of the In Vivo Antitumor Efficacy of Cisplatin-Based Doublet Therapy in Non-Small Cell Lung Cancer (NSCLC) through a …
E Kolokotroni, D Dionysiou, C Veith… - PLoS …, 2016 - ui.adsabs.harvard.edu
In Silico Oncology: Quantification of the In Vivo Antitumor Efficacy of Cisplatin-Based Doublet
Therapy in Non-Small Cell Lung Cancer (NSCLC) through a Multiscale Mechanistic Model …
Therapy in Non-Small Cell Lung Cancer (NSCLC) through a Multiscale Mechanistic Model …
[PDF][PDF] In Silico Oncology: Quantificationof the
DD KolokotroniE, C Veith, YJ Kim, J Sabczynski… - 2016 - researchgate.net
The 5-year survival of non-small cell lung cancer patients can be as low as 1% in advanced
stages. For patients with resectable disease, the successful choice of preoperative …
stages. For patients with resectable disease, the successful choice of preoperative …
In Silico Oncology: Quantification of the In Vivo Antitumor Efficacy of Cisplatin-Based Doublet Therapy in Non-Small Cell Lung Cancer (NSCLC) through a Multiscale …
E Kolokotroni, D Dionysiou, C Veith… - PLoS …, 2016 - pubmed.ncbi.nlm.nih.gov
The 5-year survival of non-small cell lung cancer patients can be as low as 1% in advanced
stages. For patients with resectable disease, the successful choice of preoperative …
stages. For patients with resectable disease, the successful choice of preoperative …
In Silico Oncology: Quantification of the In Vivo Antitumor Efficacy of Cisplatin-Based Doublet Therapy in Non-Small Cell Lung Cancer (NSCLC) through a Multiscale …
E Kolokotroni, D Dionysiou, C Veith, YJ Kim… - 2016 - agris.fao.org
The 5-year survival of non-small cell lung cancer patients can be as low as 1% in advanced
stages. For patients with resectable disease, the successful choice of preoperative …
stages. For patients with resectable disease, the successful choice of preoperative …
In Silico Oncology: Quantification of the In Vivo Antitumor Efficacy of Cisplatin-Based Doublet Therapy in Non-Small Cell Lung Cancer (NSCLC) through a Multiscale …
E Kolokotroni, D Dionysiou, C Veith… - PLoS …, 2016 - search.proquest.com
The 5-year survival of non-small cell lung cancer patients can be as low as 1% in advanced
stages. For patients with resectable disease, the successful choice of preoperative …
stages. For patients with resectable disease, the successful choice of preoperative …
In Silico Oncology: Quantification of the In Vivo Antitumor Efficacy of Cisplatin-Based Doublet Therapy in Non-Small Cell Lung Cancer (NSCLC) through a Multiscale …
E Kolokotroni, D Dionysiou, C Veith, YJ Kim… - PLoS Computational …, 2016 - go.gale.com
The 5-year survival of non-small cell lung cancer patients can be as low as 1% in advanced
stages. For patients with resectable disease, the successful choice of preoperative …
stages. For patients with resectable disease, the successful choice of preoperative …